Comparative preclinical activity of the folate-targetedVinca alkaloid conjugates EC140 and EC145
| Autor: | Nikki Parker, Joseph A. Reddy, Christopher P. Leamon, Marilynn Vetzel, Elaine Westrick, Iontcho Radoslavov Vlahov, Jeffrey S. Nicoson |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Cancer Research
Lung Neoplasms Time Factors Vinca Cell Survival medicine.drug_class Mice Nude Receptors Cell Surface Adenocarcinoma Pharmacology Binding Competitive Vinca alkaloid Mice chemistry.chemical_compound Folic Acid In vivo Cell Line Tumor medicine Animals Humans Vinca Alkaloids Vintafolide Mice Inbred BALB C Dose-Response Relationship Drug Molecular Structure biology Folate Receptors GPI-Anchored Biological activity Blood Proteins Neoplasms Experimental biology.organism_classification Xenograft Model Antitumor Assays In vitro Pterins Tumor Burden Oncology chemistry Biochemistry Folate receptor Drug Screening Assays Antitumor Carrier Proteins Protein Binding Conjugate |
| Zdroj: | International Journal of Cancer. 121:1585-1592 |
| ISSN: | 1097-0215 0020-7136 |
| DOI: | 10.1002/ijc.22853 |
| Popis: | EC140 is a water soluble folate conjugate of desacetylvinblastine monohydrazide (DAVLBH), which is constructed with an endosome-cleavable acyl hydrazone bond. This agent has proven to be active and specific against well established, subcutaneous folate receptor (FR)-positive tumors in multiple animal models. Recent structure-activity and optimization studies have yielded a disulfide bond-containing counterpart to EC140, herein referred to as EC145. This new conjugate was found to retain high affinity for FR-positive cells, and it produced specific, dose-responsive activity in vitro. Comparative in vivo efficacy tests confirmed that, like EC140, EC145 displays activity against both syngeneic and xenograft tumor models. However, EC145 was found to be more active and better tolerated than EC140; hence, more durable complete responses were consistently observed in EC145-treated tumor-bearing animals. Furthermore, EC145 was not found to be active against a FR-negative tumor model. Additional preclinical studies are therefore warranted to better understand EC145's breadth of activity against FR-positive tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text